New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
15:10 EDTLCILannett announces renewal of universal shelf registration statement
Lannett announced that the renewal of its universal shelf registration statement on Form S-3 was declared effective by the SEC. The universal shelf registration statement replaces the company's previous shelf registration statement, which expired on November 20. The universal shelf registration statement permits the company to offer and sell, from time to time, on a continuous or delayed basis in the future, up to $63.75M of equity, debt or other types of securities described in the shelf registration statement, or any combination of such securities, in one or more future public offerings. The shelf registration statement also allowscertain shareholders to sell up to $57.5M of the company's common stock. The company will not receive any proceeds from the sale of these shares. The company's prior shelf registration statement permitted the company to offer up to $80M of securities and permitted certain shareholders to sell up to $70M of the company's common stock. The new shelf registration statement represents the unsold portion of the securities registered pursuant to the prior shelf registration statement.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:29 EDTLCILannett launches Oxycodone Hydrochloride Oral Solution
Lannett Company announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price were approximately $43M. “We previously expected to begin marketing our Oxycodone Hydrochloride Oral Solution product in the second half of our fiscal year,” said Arthur P. Bedrosian, president and CEO of Lannett. “The earlier than anticipated launch combined with continued strong sales of our Digoxin product in the first quarter provide us with additional confidence to reaffirm our financial guidance for the fiscal 2015 full year.”
September 17, 2014
11:01 EDTLCIActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
September 16, 2014
07:55 EDTLCILannett voluntarily conducts internal review in response to CT AG inquiry
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use